

Executive Licensing Panel - minutes

Centre 0109 (King's Fertility)

Variation of Licensed Activities to include embryo testing

Tuesday, 23 July 2019

HFEA, 10 Spring Gardens, London SW1A 2BU

Panel members	Clare Ettinghausen (Chair) Kathleen Sarsfield-Watson Howard Ryan	Director of Strategy and Corporate Affairs Communications Manager Data Analyst
Members of the Executive	Bernice Ash	Secretary
External adviser		
Observers	Catherine Burwood Moya Berry	Licensing Manager Committee Officer

Declarations of interest

- Members of the panel declared that they had no conflicts of interest in relation to this item.

The panel had before it:

- 9th edition of the HFEA Code of Practice
- Standard licensing and approvals pack for committee members.

1. Consideration of application

- 1.1. The panel considered the papers, which included a licence variation application, report and licensing minutes for the past three years.
- 1.2. The panel noted that King's Fertility has held a licence with the HFEA since July 1992. The centre provides a full range of fertility services and has two transport centres, Epsom and St Helier NHS Trust (0259) and Kingston Hospital Assisted Conception Unit (0270).
- 1.3. The panel noted that the centre submitted an application to add embryo testing to its licence on 29 May 2019.
- 1.4. The panel noted that, at the centre's last interim inspection in April 2019, recommendations were made in relation to two major and one 'other' area of non-compliance. Since the inspection, the Person Responsible (PR) has provided evidence that actions have been taken to implement all the recommendations made in the report, and has committed, where required, to audit the effectiveness of those actions within the required timescales.
- 1.5. The panel noted that the Person Responsible (PR) had indicated that only PGT-A, also known as pre-implantation genetic screening (PGS), will be offered. It is anticipated that approximately 30 cycles will be performed each year. The biopsies will take place at centre 0295 and a third party laboratory will complete genetic testing of those biopsied cells.
- 1.6. The panel noted a desk based assessment was conducted on 12 June 2019; an additional on-site inspection was considered unnecessary as the unannounced interim inspection, which occurred in April 2019, found that the centre's premises and practices were suitable such that the inspection team recommended the continuation of the centre's licence.
- 1.7. The panel noted that at the time of the assessment, there were no areas of practice that required improvement.
- 1.8. The panel noted that the inspectorate reviewed evidence provided by the centre against the requirements of the Human Fertilisation and Embryology Act 1990 (as amended), General Directions, Standard Licence Conditions (SLCs) and the Code of Practice (CoP), with the following findings.
 - **Staff** - The centre has competent staff to carry out embryo biopsy.

The centre has submitted documented evidence of the training provided to, and the competence of, the embryologists to perform embryo biopsy (SLC T15a).

Provisions are in place for patients to have access to a genetic counsellor (CoP guidance 9.1).
 - **Equipment** - The centre has suitable equipment needed to carry out embryo testing. The centre has submitted documentation demonstrating that the equipment that will be used for embryo biopsy has been validated and is serviced regularly (SLC T24).
 - **Processes** - The centre has standard operating procedures describing the treatment pathways for PGS and PGD, the embryo biopsy process and the preparation and transport of biopsied samples to the testing laboratory (SLC T33b). The treatment pathways and processes described are compliant with HFEA requirements.

The PR clearly stated in standard operating procedures and patient information that information derived from genetic testing will not be used to select embryos of a particular sex for social reasons (SLC T88b).

Quality indicators have been established, including embryo damage rates post biopsy (SLC T35).

Evidence has been provided to demonstrate that the embryo biopsy process has been validated (SLC T72).

- **Genetic Testing** - The genetic testing will be carried out by Igenomix UK Ltd. This laboratory has achieved ISO 15189: 2012 Accreditation (SLC T21).

The centre has provided a third-party agreement with Igenomix UK Ltd that it is compliant with requirements (SLC T111, T112, T113 and T114).

- **Patient information** – Patient information has been submitted which provides all relevant information to meet the requirements set out in the Code of Practice (SLC T58).

1.9. The panel noted the inspectorate’s recommendation to vary the centre’s treatment (including embryo testing) and storage licence to include embryo testing without additional conditions.

2. Decision

2.1. The panel had regard to its decision tree. It was satisfied that the appropriate application had been submitted and that the application contained the supporting information required by General Directions 0008.

2.2. The panel endorsed the inspectorate’s recommendation to vary the centre’s licence to add embryo testing and thereby, to change the licence to treatment (including embryo testing) and storage, in accordance with Section 18A of the HFE Act 1990 (as amended).

3. Chair’s signature

3.1. I confirm this is a true and accurate record of the meeting.

Signature



Name

Clare Ettinghausen

Date

30 July 2019

Licence Variation Application Report



Inspector: Louise Winstone

Date of assessment: 12 June 2019

Date of Executive Licensing Panel: 23 July 2019

Purpose of report: Desk-based assessment of the centre's application to vary its licence to include embryo testing.

Centre details

Centre name	King's Fertility
Centre number	0109
Licence number	L/0109/14/e
Centre address	Fetal Medicine Research Institute, 1st Floor, 16-20 Windsor Walk, Denmark Hill, London, SE5 8BB, United Kingdom
Person Responsible	Mr Ippokratis Sarris
Licence Holder	Professor Kyprianos Nicolaidis
Date licence issued	1 October 2017
Licence expiry date	30 September 2021
Additional conditions applied to this licence	None

Contents

	Page
Centre details	1
Contents	2
Report to Executive Licensing Panel	3
Brief description of the centre and its licensing history	
Activities of the centre	
Summary for licensing decision	
Recommendation to the Executive Licensing Panel	
Areas of practice that require the attention of the Person Responsible and the Person Responsible response to these findings	6
Critical area of non-compliance	
Major area of non-compliance	
Other area of practice that requires consideration	

Report to Executive Licensing Panel

Brief description of the centre and its licensing history:

King's Fertility has held a licence with the HFEA since July 1992.

The centre provides a full range of fertility services and has two transport centres, Epsom and St Helier NHS Trust (0259) and Kingston Hospital Assisted Conception Unit (0270).

The centre provided 1,396 cycles of treatment (excluding partner intrauterine insemination) in the 12 months to 31 March 2019. In relation to activity levels this is a large centre.

The centre's licence was varied in February 2019 to reflect a change of premises.

The centre submitted an application to add embryo testing to its licence on 29 May 2019.

At the centre's last interim inspection in April 2019, recommendations were made in relation to two major and one 'other' area of non-compliance. Since the inspection, the Person Responsible (PR) has provided evidence that actions have been taken to implement all the recommendations made in the report, and has committed, where required, to audit the effectiveness of those actions within the required timescales.

Summary for licensing decision

In considering overall compliance, the inspection team considers that they have sufficient information drawn from documentation submitted by the centre to conclude that:

- the premises are suitable for carrying out embryo testing;
- the practices are suitable for carrying out embryo testing;
- the centre has submitted appropriately completed documentation in accordance with General Direction 0008, for variation of their licence.

The Executive Licensing Panel is asked to note that there are no areas of practice that require improvement.

Recommendation to the Executive Licensing Panel

The inspection team considers that overall there is sufficient information available to recommend the variation of this centre's licence to include embryo testing without additional conditions.

Details of assessment findings

The licence variation application

An application has been received from the PR at centre 0109 to vary the centre's licence to add embryo testing as an additional licensed activity. The centre plan to perform PGT-A (PGS), PGT-M and PGT-SR (PGD). Biopsies will take place at centre 0109 and a third-party laboratory will complete genetic testing of those biopsied cells.

The applicant has complied with all the requirements of General Direction 0008 (paragraph 6) in submitting the following:

- an application form;
- copies of information provided to patients relating to the new activity;
- evidence that the equipment and processes used in carrying out the new activity have been validated;
- a schedule of the quality indicators, and the reporting arrangements, established for this activity.

Desk-based assessment of the application

An additional on-site inspection at the centre was considered unnecessary. The centre underwent an unannounced interim inspection in April 2019, which found that the centre's premises and practices were suitable such that the inspection team recommended the continuation of the centre's licence.

Assessment findings:

Evidence provided by the centre was reviewed against the requirements of the Human Fertilisation and Embryology Act 1990 (as amended), General Directions, Standard Licence Conditions (SLCs) and the Code of Practice (CoP), with the following findings:

A. Staff

The centre has competent staff to carry out embryo biopsy.

The centre has submitted documented evidence of the training provided to, and the competence of, the embryologists to perform embryo biopsy (SLC T15a). Provisions are in place for patients to have access to a genetic counsellor (CoP guidance 9.1).

B. Equipment

The centre has suitable equipment to carry out embryo testing. The equipment that will be used for embryo biopsy has been validated and is serviced regularly (SLC T24).

C. Processes

The centre has standard operating procedures describing the treatment pathways for PGS and PGD, the embryo biopsy process and the preparation and transport of biopsied samples to the testing laboratory (SLC T33b). The treatment pathways and processes described are compliant with HFEA requirements.

It is clearly stated in patient information that information derived from genetic testing will not be used to select embryos of a particular sex for social reasons (SLC T88b).

Quality indicators have been established, including embryo damage rates post biopsy (SLC T35).

Evidence has been provided to demonstrate that the embryo biopsy process has been validated (SLC T72).

D. Genetic testing

The genetic testing will be carried out by Igenomix UK Ltd. The PR has provided the UKAS accreditation certificate in support of this application to confirm that this laboratory has achieved UKAS Accreditation for the tests specified (SLC T21).

The centre has provided a third party agreement with Igenomix UK Ltd that is compliant with requirements (SLC T111, T112, T113 and T114).

E. Patient information

Patient information has been submitted which provides all relevant information to meet the requirements set out in the Code of Practice (SLC T58).

Areas of practice that require the attention of the Person Responsible

This section sets out matters which the inspection team considers may constitute areas of non-compliance. These have been classified into critical, major and others. Each area of non-compliance is referenced to the relevant sections of the Acts, Regulations, Standard Licence Conditions, Directions or the Code of Practice, and the recommended improvement actions required are given, as well as the timescales in which these improvements should be carried out.

 **Critical area of non-compliance**

A critical area of non-compliance is an area of practice which poses a significant risk of causing harm to a patient, donor, embryo or to a child who may be born as a result of treatment services. A critical area of non-compliance requires immediate action to be taken by the Person Responsible.

Area of practice and reference	Action required and timescale for action	PR Response	Executive Review
None			



Major area of non-compliance

A major area of non-compliance is a non-critical area of non-compliance:

- which poses an indirect risk to the safety of a patient, donor, embryo or to a child who may be born as a result of treatment services;
- which indicates a major shortcoming from the statutory requirements;
- which indicates a failure of the Person Responsible to carry out his/her legal duties
- a combination of several “other” areas of non-compliance, none of which on their own may be major but which together may represent a major area of non-compliance.

Area of practice and reference	Action required and timescale for action	PR Response	Executive Review
None			

▶ **Other areas of practice that requires improvement**

Other areas of practice that require improvement is any area of practice, which cannot be classified as either a critical or major area of non-compliance, but which indicates a departure from statutory requirements or good practice.

Area of practice and reference	Action required and timescale for action	PR Response	Executive Review
None			

Additional information from the Person Responsible